化疗患者5-羟色胺3受体拮抗剂路径化管理模式的建立与应用
x
请在关注微信后,向客服人员索取文件
篇名: | 化疗患者5-羟色胺3受体拮抗剂路径化管理模式的建立与应用 |
TITLE: | Establishment and application of path-based management mode of 5-HT3 receptor antagonists in chemotherapy patients |
摘要: | 目的 建立化疗患者5-羟色胺3受体拮抗剂(5-HT3RA)路径化管理模式,提高化疗患者用药合理性。方法制定5-HT3RA规范化用药管控规则,并借助医疗智能及决策支持(MINDS)系统,以信息抓取结合医嘱前置审核的形式对使用5-HT3RA的化疗患者开展路径化管理,对用药指征、用法用量、疗程等实施全程化干预。通过比较实施路径化管理前后5-HT3RA无指征用药、用法用量不合理、重复用药、疗程不合理的变化情况以及5-HT3RA人均药费变化情况,对干预效果进行分析。结果共纳入9181例患者,实施路径化管理后,无指征用药率降低0.48%,单次剂量、给药频次、重复用药、疗程(化疗结束后3d仍使用5-HT3RA)的不合理率分别降低10.48%、0.65%、1.33%、0.34%,5-HT3RA人均药费降低13.72元,以上差异均有统计学意义(P<0.05)。结论我院建立的化疗患者5-HT3RA路径化管理模式有效提高了用药合理性,为临床合理用药提供了新思路。 |
ABSTRACT: | OBJECTIVE To establish the path-based management mode of 5-hydroxytryptamine-3 receptor antagonist (5- HT3RA) in chemotherapy patients, and to improve the rationality of medication in chemotherapy patients. METHODS 5-HT3RA standardized drug use control rules were formulated, with the help of medical intelligence and decision support (MINDS) system, path-based management was carried out for chemotherapy patients using 5-HT3RA in the form of whole-process information capture and prescription pre-review, and whole-process intervention was implemented on medication indications, usage and dosage, course of treatment, etc. The intervention effect was analyzed by comparing the changes in the use of 5-HT3RA without indication, unreasonable usage and dosage, repeated medication, unreasonable course of treatment, and per capita drug cost before and after the implementation of path-based management. RESULTS A total of 9 181 patients were included. After the implementation of path- based management, the proportion of unindicated drugs decreased by 0.48%, and the rate of unreasonable single dosage, unreasonable frequency, repeated medication, unreasonable treatment course (5-HT3RA still used 3 days after chemotherapy) decreased by 10.48%, 0.65%, 1.33% and 0.34%; per capita cost of 5-HT3RA decreased by 13.72 yuan; there were statistical significance (P<0.05). CONCLUSIONS 5-HT3RA path-based management mode effectively improves the rationality of medication and provides a new idea for rational clinical drug use. |
期刊: | 2023年第34卷第04期 |
作者: | 高璐;李静;周晓;黄元;虞琳;宋慧珠;杨钰华 |
AUTHORS: | GAO Lu,LI Jing,ZHOU Xiao,HUANG Yuan,YU Lin,SONG Huizhu,YANG Yuhua |
关键字: | 5-羟色胺3受体拮抗剂;化疗患者;路径化管理;信息化 |
KEYWORDS: | 5-hydroxytryptamine-3 receptor antagonist; chemotherapy patients; path-based management; informatization |
阅读数: | 182 次 |
本月下载数: | 5 次 |
* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!